Altium Cares

Beyond Weight Loss: The Surprising Future of GLP-1 Drugs The GLP-1 receptor agonist market in the U.S. is quite significant. As of 2024, the market size for drugs like semaglutide and tirzepatide is estimated to be around $11.99 billion, with expected growth to $12.63 billion by 2029. The growth has been largely driven by the increasing prevalence of diabetes and obesity. Now, promising benefits in several other areas suggest the potential for even more significant market expansion. Here's why ⬇️ Repurposing Opportunities: Many are familiar with successful pharmaceutical discoveries of side therapies like Sildenafil, the angina drug that became Viagra, a game-changing treatment in the $2.94 billion erectile dysfunction market. Similarly, Minoxidil, initially a blood pressure medication, is now commonly used to treat hair loss, with its global market estimated at $1.5 billion. Recently, researchers have discovered that semaglutide (Ozempic and Wegovy by Novo Nordisk) and tirzepatide (Mounjaro and Zepbound by Eli Lilly and Company) may have potential benefits for other conditions, among them addiction treatment, reduction of Alzheimer's risk, and help for glaucoma patients. Investigations Include: Treating Substance Use Disorders: GLP-1 receptor agonists show promise in treating substance use disorders, including alcohol, opioid, and tobacco addiction. A Swedish observational study found these drugs may help reduce cravings and withdrawal symptoms in patients with alcohol use disorder. Reducing Alzheimer's Risk: Novo Nordisk is conducting a 77-week study, including a 12-week randomized placebo-controlled trial, investigating semaglutide's effects on immune system function and biological processes in Alzheimer's patients. The research aims to understand potential cognitive benefits and effects on amyloid plaque accumulation. Benefits for Some Glaucoma Patients: Clinical trials have identified potential risks of worsening retinopathy with medications like liraglutide and semaglutide. However, the drugs show promising benefits in reducing glaucoma risk by potentially reducing intraocular pressure and protecting retinal cells. Market Considerations: While expanded applications may grow the market for GLP-1 receptors, risks include supply chain issues affecting availability and potential regulatory delays as new uses and side effects are investigated for safety and efficacy. #GLP1 #Tirzepatide #HealthcareInnovation #PharmaTrends #DrugRepurposing #Biotech #DiabetesTreatment #AlzheimersResearch #AddictionTreatment Disclaimer: This post is for informational purposes only and reflects my personal views. It is not intended as medical advice, financial advice, or an endorsement of any company. Please consult with qualified professionals for guidance specific to your situation.

🚨 Groundbreaking News in Leukemia Treatment! The FDA has approved revumenib (Revuforj®), the first drug of its kind to treat advanced acute myeloid leukemia (AML) in adults and children as young as 1 year old with a specific gene mutation. This breakthrough could mean longer, healthier lives for patients facing limited treatment options. The Leukemia & Lymphoma Society (LLS) played a critical role in advancing this life-changing therapy through decades of research and support. Learn more about this milestone in the fight against blood cancer and how it’s changing lives: https://lnkd.in/gP7yYzUi #MedicalNews #Leukemia #CancerResearch #MedicalResearch #FDAApproved

As the seasons change, so can our moods. Learn about Seasonal Affective Disorder (SAD), its signs, causes, and available treatments. Prioritize your mental health and stay informed this season. 💛 Swipe through to learn more and remember—help is always within reach. For more information, visit National Institute of Mental Health (NIMH): https://lnkd.in/eUfMz_7F #MentalHealth #SeasonalAffectiveDisorder #Depression #SelfCare #LightTherapy

Change starts with us. Together, even small actions can make a big difference. 🌍 #MakeADifference #CommunityPower #TogetherWeCan #BeTheChange #PositiveImpact

🎗️ Childhood cancer remains the leading cause of disease-related death among children in the U.S. While progress has been made, more research is essential to develop safer, more effective treatments and improve long-term outcomes for survivors. Swipe through to learn how research drives progress and what’s being done to advance care for children facing cancer. 👉 Learn more about ongoing research efforts and how you can support the fight against childhood cancer: https://lnkd.in/dCmsU9aT #ChildhoodCancer #CancerResearch #EndCancer #ResearchMatters #MedicalResearch

A new The National Institutes of Health study reveals that cancer prevention and screening have saved more lives than treatment advances for five major cancer types over the past 45 years. Breast, cervical, colorectal, lung, and prostate cancers saw 80% of deaths averted thanks to efforts like smoking cessation, early detection, and routine screenings. 💡 Prevention and screening aren’t just options—they’re lifesaving measures. 📖 Read the study to learn more about these findings: https://lnkd.in/eiB-H5W9 #CancerResearch #MedicalResearch #CancerAwareness #HealthMatters #CancerScreening

A new study from the Keck School of Medicine of the University of Southern California reveals that adults generate new brain cells to support verbal learning and memory—key for engaging in conversations and remembering what we hear. Using brain tissue from epilepsy patients, researchers uncovered a strong link between neurogenesis and cognitive function, opening doors to potential treatments for learning and memory challenges. This discovery could pave the way for therapies to boost brain health through exercise, medication, or innovative approaches. 🌟 Keep your mind engaged—your brain is always learning! 🔗 Read more: https://lnkd.in/gXZ3kNVS #BrainHealth #HealthNews #MedicalResearch #HealthInnovation #Neuroscience

Exciting developments from UMass Amherst researchers could reshape the landscape of metabolic disease treatment. Led by distinguished biomedical engineer Dr. S. Thai Thayumanavan, scientists have developed an innovative nanogel delivery system for Thyromimetic drugs that shows remarkable results in treating cardiometabolic disorder, obesity, and high cholesterol. Key Highlights: • Revolutionary nanogel technology delivers thyroid-mimicking drugs directly to liver cells, where they break down and release medication that regulates metabolism and fat processing. • In studies, mice treated with nanogel lost excess weight while maintaining their high-calorie diets. • The treatment normalized cholesterol levels, reduced liver inflammation, and increased fat metabolism without adverse side effects. Why This Matters: With 100 million Americans affected by obesity and cardiometabolic disorders, the market potential is significant. This technology stands out for its precision delivery system, addressing previous challenges with thyroid hormone treatments. Investment Perspective: While promising mouse results require extensive testing before human drug development begins, the targeted drug delivery systems sector offers compelling opportunities. Dr. Thayumanavan has launched Cyta Therapeutics to develop this technology, transitioning from academic research to commercial development. Cyta Therapeutics recently earned recognition as Best Startup at Boston's prestigious Massachusetts Life Sciences Innovation Day. Factors to Watch: • Clinical trial progression • FDA approval pathway • Market competition analysis • Development timeline for human trials For investors interested in this space, consider: 1. Companies developing innovative drug delivery platforms 2. Biotechnology firms focused on metabolic disorders 3. Healthcare-focused ETFs offer diversified exposure, though healthcare policy changes and other political factors may influence sector performance. 𝗥𝗲𝗺𝗲𝗺𝗯𝗲𝗿: While early-stage biotech investments can offer significant potential returns, they also carry substantial risks. Success in animal studies doesn't guarantee human trial outcomes. 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘊𝘰𝘯𝘴𝘶𝘭𝘵 𝘸𝘪𝘵𝘩 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘴𝘰𝘳𝘴 𝘣𝘦𝘧𝘰𝘳𝘦 𝘮𝘢𝘬𝘪𝘯𝘨 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴. #BiotechInnovation #DrugDelivery #MetabolicHealth #LifeSciences #UMassResearch

🌟 This #GivingTuesday, your generosity can spark hope. At Altium Cares, we're not just collecting donations – we're investing in medical breakthroughs that could change lives. Whether you donate stocks, crypto, or through traditional methods, every contribution moves us closer to innovative healthcare solutions. 🔬 Together, we can make a real difference. Donate now at altiumcares.org/donate #MedicalResearch #Healthcare #NonProfit #GiveBack 

The FDA has approved Cologuard Plus, Exact Sciences' next-generation advancement in colorectal cancer (CRC) screening technology. This non-invasive test represents a significant leap forward in early detection capabilities. Key Features and Benefits 1.  Improved Accuracy: 95% sensitivity for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity. 2.  Reduced False Positives: Minimizes unnecessary follow-up colonoscopies. 3.  Non-Invasive Option: Home-based test encourages higher participation in screening. Public Health Impact ⏱️ Early Detection: Improves survival rates by identifying precancerous growths for millions overdue for screening. ⩥ Increased Accessibility: Offers an alternative to more invasive methods, potentially increasing screening rates. 💵 Cost-Effective: Fewer false positives reduce unnecessary procedures, saving healthcare costs and reducing patient anxiety. The Bigger Picture Exact Sciences expects to launch Cologuard Plus with Medicare coverage and guideline inclusion in early 2025, potentially revolutionizing CRC screening and prevention strategies and positioning itself as a frontrunner in the cancer diagnostics market. This FDA approval could be a catalyst for both short-term stock price movement and long-term growth prospects. While the financial aspects of such developments are noteworthy, the real victory lies in the potential to save lives and improve patient care. Upcoming Novel CRC Screening Technologies Other innovative companies are revolutionizing colorectal cancer screening with cutting-edge technologies in clinical trials or awaiting FDA approval. In the final stages of development, Freenome leverages machine learning and multi-omics for a blood-based test, potentially offering a non-invasive, highly accurate screening method. FDA-approved and awaiting commercial launch is Geneoscopy's stool-based RNA test, which is expected to launch later this year or early 2025.  It aims to improve detection rates of both cancer and precancerous lesions. CellMax Life's FirstSight blood test utilizes circulating tumor cell technology, promising early detection with a simple blood draw. These approaches could significantly disrupt the CRC screening market, offering improved accuracy, convenience, and early detection capabilities. As these technologies progress, they present intriguing opportunities in the rapidly evolving cancer diagnostics sector. #CancerScreening #HealthTech #FDAApproved #PublicHealth #MedicalInnovation